Australia - English - Department of Health (Therapeutic Goods Administration)

the trustee for greenoia wellness - crateva magna, quantity: 175 mg (equivalent: crateva magna, qty 1.75 g); cucurbita pepo, quantity: 450 mg (equivalent: cucurbita pepo, qty 9 g); glycine max, quantity: 62.5 mg (equivalent: glycine max, qty 10 g); fucus vesiculosus, quantity: 100 mg (equivalent: fucus vesiculosus, qty 500 mg; equivalent: iodine, qty 120 microgram) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; povidone; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; hypromellose; macrogol 400; carnauba wax; iron oxide red - traditionally used in western herbal medicine to maintain/support healthy bladder function ; traditionally used in western herbal medicine to helps enhance/promote bladder health ; traditionally used in western herbal medicine to bladder tonic/enhance bladder health ; decrease/reduce/relieve urinary incontinence associated with medically diagnosed overactive bladder ; decrease/reduce/relieve urinary urgency associated with medically diagnosed overactive bladder ; relieve urinary frequency ; traditionally used in western herbal medicine to maintain/support healthy urine output

Australia - English - Department of Health (Therapeutic Goods Administration)

caruso's natural health pty ltd - crateva magna, quantity: 150 mg (equivalent: crateva magna, qty 1.5 g); cucurbita pepo, quantity: 437.5 mg (equivalent: cucurbita pepo, qty 8.75 g); glycine max, quantity: 83.5 mg (equivalent: glycine max, qty 13.36 g); conifer phytosterol complex, quantity: 92.86 mg (equivalent: sitosterol, qty 65 mg) - tablet, film coated - excipient ingredients: maltodextrin; povidone; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; crospovidone; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 400; carnauba wax - help maintain/support healthy prostate function ; maintain/support prostate health ; maintain/support healthy bladder function ; maintain/support bladder health ; maintain/support urinary tract health ; maintain/support urinary tract function ; maintain/support urogenital health ; maintain/support healthy urine output

Australia - English - Department of Health (Therapeutic Goods Administration)

magnolia health products pty ltd - crateva nurvala,equisetum arvense,lycopene,selenomethionine,serenoa repens,zinc amino acid chelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

seipel group pty ltd - crateva nurvala,equisetum arvense,lindera strychnifolia -

Australia - English - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - crateva nurvala,equisetum arvense,lycopersicon esculentum,selenomethionine,serenoa repens,zinc citrate -

Malta - English - Medicines Authority

actavis group ptc ehf - granisetron hydrochloride - coated tablet - granisetron hydrochloride 1.12 mg - antiemetics and antinauseants

Malta - English - Medicines Authority

actavis group ptc ehf - granisetron hydrochloride - coated tablet - granisetron hydrochloride 2.24 mg - antiemetics and antinauseants

Malta - English - Medicines Authority

sigillata limited - granisetron hydrochloride - film-coated tablet - granisetron hydrochloride 1.12 milligram(s) - antiemetics and antinauseants

Malta - English - Medicines Authority

sigillata limited - granisetron hydrochloride - film-coated tablet - granisetron hydrochloride 2.24 milligram(s) - antiemetics and antinauseants

European Union - English - EMA (European Medicines Agency)

nordic group b.v. - methotrexate - arthritis, psoriatic, psoriasis, arthritis, juvenile rheumatoid, arthritis, rheumatoid - antineoplastic agents, - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet a (puva), and retinoids, and severe psoriatic arthritis in adult patients.